These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 29581249)

  • 1. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
    Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
    Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
    Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
    Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3
    Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY
    Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
    Bernhardt WM; Câmpean V; Kany S; Jürgensen JS; Weidemann A; Warnecke C; Arend M; Klaus S; Günzler V; Amann K; Willam C; Wiesener MS; Eckardt KU
    J Am Soc Nephrol; 2006 Jul; 17(7):1970-8. PubMed ID: 16762988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roxadustat (FG-4592) protects against ischaemia/reperfusion-induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice.
    Zhang M; Dong R; Yuan J; Da J; Zha Y; Long Y
    Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):311-318. PubMed ID: 34653291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2.
    Yang Y; Liu S; Gao H; Wang P; Zhang Y; Zhang A; Jia Z; Huang S
    Free Radic Biol Med; 2020 May; 152():821-837. PubMed ID: 32004633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
    Beck J; Henschel C; Chou J; Lin A; Del Balzo U
    Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
    Huang H; Wang X; Zhang X; Wang H; Jiang W
    Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization.
    Tang D; Zhang J; Yan T; Wei J; Jiang X; Zhang D; Zhang Q; Jia J; Huang Y
    Cell Physiol Biochem; 2018; 46(6):2460-2470. PubMed ID: 29742498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.
    Yu J; Wang S; Shi W; Zhou W; Niu Y; Huang S; Zhang Y; Zhang A; Jia Z
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF activation protects from acute kidney injury.
    Weidemann A; Bernhardt WM; Klanke B; Daniel C; Buchholz B; Câmpean V; Amann K; Warnecke C; Wiesener MS; Eckardt KU; Willam C
    J Am Soc Nephrol; 2008 Mar; 19(3):486-94. PubMed ID: 18256363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
    Chang WT; Lo YC; Gao ZH; Wu SN
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilizing HIF to Ameliorate Anemia.
    Voit RA; Sankaran VG
    Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury.
    Kapitsinou PP; Jaffe J; Michael M; Swan CE; Duffy KJ; Erickson-Miller CL; Haase VH
    Am J Physiol Renal Physiol; 2012 May; 302(9):F1172-9. PubMed ID: 22262480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation.
    Yang H; Wu Y; Cheng M; Zhang M; Qiu X; Liu S; Zhang M
    Nephrol Dial Transplant; 2023 Mar; 38(4):858-875. PubMed ID: 36413468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.
    Wu K; Zhou K; Wang Y; Zhou Y; Tian N; Wu Y; Chen D; Zhang D; Wang X; Xu H; Zhang X
    Brain Res; 2016 Feb; 1632():19-26. PubMed ID: 26707978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.